Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | K59del |
Impact List | deletion |
Protein Effect | unknown |
Gene Variant Descriptions | MAP2K1 K59del results in the deletion of an amino acid in the protein kinase domain of the Map2k1 protein at amino acid 59 (UniProt.org). K59del results in increased Mek and Erk phosphorylation in culture (PMID: 22389471), but demonstrates autophosphorylation levels similar to wild-type Map2k1 in another study (PMID: 29753091), and therefore, its effect on Map2k1 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 K59del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435121_66435123delAAG |
cDNA | c.175_177delAAG |
Protein | p.K59delK |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002755.4 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66485000_66485002delTCC | c.176_178delTCC | p.L59delL | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66485000_66485002delTCC | c.176_178delTCC | p.L59delL | RefSeq | GRCh38/hg38 |
XM_011521783.3 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66435121_66435123delAAG | c.175_177delAAG | p.K59delK | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66435190_66435192delGTG | c.178_180delGTG | p.V60delV | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 K59del | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K59del in culture (PMID: 36442478). | 36442478 |